
    
      This is a Phase 1, single center, randomized, double blind, single ascending dose (SAD) and
      multiple ascending dose (MAD) study to assess the safety and pharmacokinetics of ANA001 in
      healthy adult subjects. In the single ascending dose portion of the study, subjects in 3
      cohorts of 10 subjects each will be randomized to receive a single daily oral dose of ANA001
      or matching placebo. In the multiple ascending dose portion of the study, subjects in 3
      cohorts of 12 subjects each will be randomized to receive twice or thrice daily oral dose of
      ANA001 or matching placebo.
    
  